Update – Ocrelizumab for Primary Progressive MS in Canterbury
On Wednesday 15 May, Multiple Sclerosis NZ raised how critical workforce shortages are impacting patients with Primary Progressive MS (PPMS) access to time sensitive disease modifying therapies. A business case prepared by clinical specialists had been under review for five months asking for more resourcing to meet patient needs and ensure safe levels of working […]
Press Release: Access to Life-Changing MS Drug “snatched away” Due to Staff Shortages
A celebrated Pharmac decision late last year to fund a vital drug for many Multiple Sclerosis patients has fallen flat – with dozens being turned away for treatment due to severely stretched resources across a number of services. Multiple Sclerosis New Zealand (MSNZ) says one particular Health New Zealand (HNZ) region – Canterbury Waitaha – […]
Media Release: “Relief” over Pharmac Decision to Fund First-Ever Treatment for Debilitating Form of Multiple Sclerosis
A seven year battle on behalf of hundreds of people living with the most debilitating form of Multiple Sclerosis has been won – with Pharmac agreeing to fund Aotearoa New Zealand’s first ever treatment for the disease variant from October 1st. Multiple Sclerosis New Zealand (MSNZ) says the decision to fund Ocrelizumab is hugely positive […]
MS in the News: Funded treatment for primary progressive multiple sclerosis
Te Pātaka Whaioranga – Pharmac has started a consultation today for widening access for two treatments; ocrelizumab (branded as Ocrevus) as the first funded treatment for primary progressive multiple sclerosis, and emicizumab (branded as Hemlibra) for the treatment of all people with severe haemophilia A. “We understand people living with these conditions are currently experiencing […]